Repligen Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Financial Guidance
Record revenue of $207.6 million for the quarter, representing overall growth of 27% as reported and 32% at constant currency (year-over-year) Strong organic revenue growth of 29% and strong base business growth of 41% for the quarter Revenue guidance raised to $790 - $810 million for full year 2022
WALTHAM, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter ended June 30, 2022. Provided in this press release are financial highlights for the three- and six-month periods ended June 30, 2022, updates to our financial guidance for the year 2022 and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “I’m very pleased with our performance for the second quarter where we generated $208 million in revenue, representing 29% year-over-year organic growth. We continue to